NYSE · ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES · LARGE CAP
Zimmer Biomet Holdings, Inc. ZBH
19 fiscal years on record · USD · FY2025 reported · SEC filings only
In brief
What this company does
Written from the business description in ZIMMER BIOMET HOLDINGS, INC.'s annual report to the U.S. Securities and Exchange Commission, filed 20 February 2026. Every sentence was checked against that document before publication.
Growth
USD 8.2B
Revenue, FY2025 · full 19-year series below
Revenue $B
Net income $B
FY2025 · Revenue 8.2 · Net income 0.7
Compound annual growth
+5.9%
+6.1%
+3.2%
+4.6%
+45.0%
+17.0%
+1.1%
+47.8%
+16.5%
+1.2%
+0.0%
+0.0%
+0.9%
+27.4%
+27.8%
+8.2%
+2.0%
3 yrs
5 yrs
10 yrs
15 yrs
Revenue compounded at +6.1% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
9 cents
of every revenue dollar became profit
Operating margin
Net margin
FY2025 · Operating 13.3% · Net 8.6%
ROE
FY2025 · ROE 5.6%
Each USD of equity produced 6 cents of profit this year.
The 19-year record
19 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 8.2 | 7.7 | 7.4 | 6.9 | 6.8 | 6.1 | 8.0 | 7.9 | 7.8 | 7.7 | 6.0 | 4.7 | 4.6 | 4.5 | 4.5 | 4.2 | 4.1 | 4.1 | 3.9 |
| Operating income $B | 1.1 | 1.3 | 1.3 | 0.7 | 0.9 | 0.1 | 1.1 | 0.0 | 0.8 | 0.8 | 0.5 | 1.0 | 1.1 | 1.0 | 1.0 | 0.9 | 1.0 | 1.1 | 1.1 |
| EBITDA $B | 2.2 | 2.3 | 2.2 | 1.6 | 1.8 | 1.0 | 2.1 | 1.1 | 1.9 | 1.9 | 1.2 | 1.4 | 1.4 | 1.4 | 1.4 | 1.3 | 1.4 | 1.4 | 1.4 |
| Income tax $B | 0.1 | 0.1 | 0.0 | 0.1 | 0.1 | −0.1 | −0.2 | 0.1 | −1.3 | 0.1 | 0.0 | 0.2 | 0.2 | 0.2 | 0.2 | 0.3 | 0.3 | 0.3 | 0.4 |
| Net income $B | 0.7 | 0.9 | 1.0 | 0.2 | 0.4 | −0.1 | 1.1 | −0.4 | 1.8 | 0.3 | 0.1 | 0.7 | 0.8 | 0.8 | 0.8 | 0.6 | 0.7 | 0.8 | 0.8 |
| Free cash flow $B | 1.5 | 1.3 | 1.3 | 1.2 | 1.3 | 1.0 | 1.4 | 1.6 | 1.4 | 1.4 | 0.7 | 0.9 | 0.9 | 1.0 | 1.1 | 1.1 | 1.0 | 0.8 | 0.9 |
| EPS, diluted $ | 3.55 | 4.43 | 4.88 | 1.10 | 1.91 | −0.67 | 5.47 | −1.86 | 8.90 | 1.51 | 0.77 | 4.20 | 4.54 | 4.29 | 4.03 | 2.97 | 3.32 | 3.72 | 3.26 |
| Dividend / sh $ | 0.96 | 0.96 | 0.96 | 0.96 | 0.96 | 0.96 | 0.96 | 0.96 | 0.96 | 0.96 | 0.88 | 0.88 | 0.80 | 0.54 | 0.18 | · | · | · | · |
| Payout % | 27 | 22 | 20 | 87 | 50 | −143 | 17 | −51 | 11 | 62 | 107 | 20 | 17 | 13 | · | · | · | · | · |
| ROE % | 5.6 | 7.2 | 8.4 | 1.9 | 3.2 | −1.1 | 9.6 | −3.3 | 16.9 | 3.1 | 1.8 | 11.2 | 12.8 | 13.3 | 13.5 | 10.5 | 12.7 | 15.0 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 82 reconciliationsAUDITED
Reconciled in 19 of 19 fiscal years. 2 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityOrthopedic, Prosthetic & Surgical Appliances & Supplies
Listed onNYSE
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2007